妊娠期2型糖尿病中使用连续血糖监测与围产期结局:系统综述与Meta分析
本系统综述与Meta分析检索Ovid MEDLINE、Scopus、ClinicalTrials.gov和Cochrane图书馆(建库至2022年5月9日),纳入3项随机对照试验,对2项无显著偏倚风险研究的56例使用连续血糖监测孕妇与53例对照孕妇进行随机效应Meta分析,发现连续血糖监测与大于胎龄儿(OR 0.78,95%CI 0.34-1.78,I²=0%)及子痫前期(OR 1.63,95%CI 0.34-7.22,I²=0%)均无显著差异。
要点
- 连续血糖监测与大于胎龄儿发生率无显著差异(OR 0.78,95%CI 0.34-1.78)。
- 连续血糖监测与子痫前期发生无显著差异(OR 1.63,95%CI 0.34-7.22)。
- 本综述受限于该人群可用数据量小,需进一步研究。
核心结论
- 连续血糖监测的使用与大于胎龄儿和子痫前期所评估的围产期结局改善无关。
- 本综述受限于该人群可用数据量小,需进一步研究。
研究设计与样本
- 系统综述与Meta分析,检索Ovid MEDLINE、Scopus、ClinicalTrials.gov和Cochrane图书馆从建库至2022年5月9日。
- 初检获得2463条唯一题录,由2名独立评价者在Covidence中筛选。
- 纳入标准为比较连续血糖监测与指尖血糖监测用于2型糖尿病孕妇的所有研究,研究类型包括随机对照试验、队列研究和横断面研究。
- 共3项随机对照试验符合纳入标准,对2项无显著偏倚风险研究进行随机效应Meta分析,报告汇总校正比值比及95%置信区间。
主要发现
- 连续血糖监测组56例与未使用连续血糖监测的对照53例相比,大于胎龄儿发生率无差异(OR 0.78,95%CI 0.34-1.78),I²=0%。
- 连续血糖监测组与标准治疗对照组相比,子痫前期发生无差异(OR 1.63,95%CI 0.34-7.22),I²=0%。
关键数值与推荐
- 大于胎龄儿:连续血糖监测组 vs 标准治疗对照组 OR 0.78(95%CI 0.34-1.78),I²=0%。
- 子痫前期:连续血糖监测组 vs 标准治疗对照组 OR 1.63(95%CI 0.34-7.22),I²=0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本综述受限于该人群可用数据量小。
- 需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to assess whether continuous glucose monitor use in type 2 diabetes mellitus in pregnancy is associated with improved perinatal outcomes. DATA SOURCES: We searched Ovid MEDLINE, Scopus, ClinicalTrials.gov, and Cochrane library from inception through May 9, 2022. STUDY ELIGIBILITY CRITERIA: We included all studies that compared continuous glucose monitor use with fingerstick glucose monitoring in women with type 2 diabetes mellitus. METHODS: The initial search yielded 2463 unique citations that were screened in Covidence by 2 independent reviewers. Study types included randomized controlled trials, cohort studies, and cross-sectional studies. Our outcomes of interest were macrosomia or large-for-gestational-age infants, hemoglobin A1c, cesarean delivery, hypertensive disorders of pregnancy including preeclampsia, gestational age at delivery, and neonatal hypoglycemia. RESULTS: Three randomized controlled trials met the inclusion criteria. We performed random-effects meta-analyses of estimates from 2 studies without risk of significant bias and reported summary adjusted odds ratios and 95% confidence intervals. Meta-analysis of 56 women with continuous glucose monitor use and 53 control women without continuous glucose monitor use showed that there was no difference in the incidence of large-for-gestational-age infants between continuous glucose monitor users and standard-of-care controls (odds ratio, 0.78; 95% confidence interval, 0.34-1.78) with an I2 of 0%. In addition, there was no difference in the development of preeclampsia between continuous glucose monitor users and standard-of-care controls (odds ratio, 1.63; 95% confidence interval, 0.34-7.22) with an I2 of 0%. CONCLUSION: Continuous glucose monitor use was not associated with improved perinatal outcomes as assessed by large-for-gestational-age infants and preeclampsia. This review is limited by the small amount of data available for this population, and further research is needed.
引用
- Wilkie G, Melnik V, Brainard L, et al. Continuous glucose monitor use in type 2 diabetes mellitus in pregnancy and perinatal outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023. PMID: 37061044. doi:10.1016/j.ajogmf.2023.100969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。